- 0Q1G, LLY Ticker
- NYSE, F, LSE, XETRA Exchange
- 38,680 Employees
- π Health Care Sector
- π©π»ββ Pharmaceuticals Industry
- David A. Ricks CEO
Financial statements β Eli Lilly
The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
| 20 β 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Total Revenue |
|
25B | 22B | 25B | 23B | 21B |
| Cost Of Revenue |
|
5.5B | 4.7B | 6.4B | 6.1B | 5.7B |
| Gross Profit |
|
19B | 18B | 18B | 17B | 16B |
| Research and Development |
|
6.1B | 5.6B | 5.3B | 5.3B | 5.2B |
| Selling General and Admin |
|
6.1B | 6.2B | 6.6B | 6.6B | 6.5B |
| Operating Expense |
|
18B | 17B | 18B | 18B | 17B |
| Operating Income |
|
6.8B | 5.8B | 6.2B | 4.9B | 3.9B |
| Other Income Expense Net |
|
0 | 0 | 0 | 0 | 0 |
| EBIT |
|
6.8B | 5.8B | 6.2B | 4.9B | 3.9B |
| Interest Income |
|
330M | 320M | 110M | 58M | 77M |
| Pretax Income |
|
7.2B | 5.3B | 3.8B | 2.2B | 3.4B |
| Income Tax |
|
1B | 630M | 560M | 2.4B | 640M |
| Minority Interest |
|
0 | 0 | 0 | 0 | 0 |
| Net Income |
|
6.2B | 8.3B | 3.2B | -200M | 2.7B |
| Net Income Basic |
|
6.2B | 8.3B | 3.2B | -200M | 2.7B |
| 20 β 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Current cash |
|
3.7B | 2.4B | 8.1B | 8B | 6B |
| Short term investments |
|
2.9B | 2.5B | 2.1B | 1.4B | 730M |
| Receivables |
|
6.9B | 5.5B | 6.2B | 5.3B | 4.8B |
| Inventory |
|
4B | 3.2B | 4.1B | 4.5B | 3.6B |
| Other current assets |
|
2.9B | 2.5B | 2.1B | 1.4B | 730M |
| Current assets |
|
17B | 14B | 21B | 19B | 15B |
| Long term investments |
|
29B | 26B | 23B | 26B | 24B |
| Property plant equipment |
|
8.7B | 7.9B | 8.9B | 8.8B | 8.3B |
| Goodwill |
|
3.8B | 3.7B | 4.3B | 4.4B | 4B |
| Intangible assets |
|
7.5B | 6.6B | 3.5B | 4B | 4.4B |
| Other assets |
|
3.5B | 2.3B | 1.9B | 2.9B | 1.9B |
| Total assets |
|
47B | 39B | 44B | 45B | 39B |
| Accounts payable |
|
1.6B | 1.4B | 1.4B | 1.4B | 1.3B |
| Current long term debt |
|
8.7M | 1.5B | 1.1B | 3.7B | 1.9B |
| Other current liabilities |
|
11B | 8.9B | 9.3B | 9.4B | 7.7B |
| Total current liabilities |
|
12B | 12B | 12B | 15B | 11B |
| Long term debt |
|
17B | 14B | 12B | 9.9B | 8.4B |
| Other liabilities |
|
9.6B | 8.3B | 9.5B | 8.8B | 5.4B |
| Minority Interest |
|
180M | 92M | 1.1B | 76M | 73M |
| Total Liabilities |
|
41B | 37B | 34B | 33B | 25B |
| Common stock |
|
910M | 930M | 1B | 1.1B | 1.1B |
| Retained earning |
|
7.8B | 4.9B | 11B | 14B | 16B |
| Treasury stock |
|
-56M | -61M | -69M | -76M | -81M |
| Capital surplus |
|
β’ | β’ | β’ | β’ | β’ |
| Shareholder equity |
|
5.6B | 2.6B | 9.8B | 12B | 14B |
| Net tangible assets |
|
-5.6B | -7.7B | 2B | 3.2B | 5.7B |
| 20 β 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Net Income |
|
6.2B | 8.3B | 3.2B | -200M | 2.7B |
| Depreciation |
|
1.3B | 1.2B | 1.6B | 1.6B | 1.5B |
| Changes in receivables |
|
1.4B | -660M | 940M | 500M | 690M |
| Changes in inventories |
|
790M | -920M | -350M | 900M | 120M |
| Cash change |
|
1.2B | -5.6B | 52M | 2B | 1.6B |
| Cash flow |
|
6.5B | 4.8B | 5.5B | 5.6B | 4.9B |
| Capital expenditures |
|
-1.4B | -1B | -1.2B | -1.1B | -1B |
| Investments |
|
β’ | β’ | β’ | β’ | β’ |
| Investing activity other |
|
β’ | β’ | β’ | β’ | β’ |
| Total investing cash flows |
|
-2.3B | -8.1B | 1.9B | -3.8B | -3.1B |
| Dividends paid |
|
2.7B | β’ | β’ | β’ | β’ |
| Net borrowings |
|
10B | 10B | 2.5B | 4.2B | 3.5B |
| Other financing cash flows |
|
β’ | β’ | β’ | β’ | β’ |
| Cash flow financing |
|
-3.1B | -2.3B | -5.9B | 140M | -560M |
| Exchange rate effect |
|
β’ | β’ | β’ | β’ | β’ |
Analyst Recommendations
This chart is a recommendation for investors. To provide forecasts, analysts and brokers use companies' public financial reports and speak with their employees and clients. The end result is a solution that's marked on the chart, which shows analysts' opinions at different periods of time. Move your cursor to track on what the dates the recommendations changed.
Investors shouldn't only follow analyst recommendations. Forecasts should be used to supplement existing strategies and plans. Trading based on a recommendation chart is is considered bad practice. Analyst reports should only be used in conjunction with your own analytics.
Also known as strong sell, it's a recommendation to sell a security or to liquidate an asset.
A recommendation that means a stock is expected to do slightly worse than the overall stock market return. Underperform can also be expressed as "moderate sell", "weak hold" and "underweight."
A company with a hold recommendation is expected to perform on par with comparable companies or in line with the market.
Also known as "moderate buy", "accumulate", and "overweight." Outperform is an analyst recommendation meaning a stock is expected to do slightly better than the market return.
Also known as strong buy and "on the recommended list." Needless to say, buy is a recommendation to purchase a specific security.
Also known as strong sell, it's a recommendation to sell a security or to liquidate an asset.
A recommendation that means a stock is expected to do slightly worse than the overall stock market return. Underperform can also be expressed as "moderate sell", "weak hold" and "underweight."
A company with a hold recommendation is expected to perform on par with comparable companies or in line with the market.
Also known as "moderate buy", "accumulate", and "overweight." Outperform is an analyst recommendation meaning a stock is expected to do slightly better than the market return.
Also known as strong buy and "on the recommended list." Needless to say, buy is a recommendation to purchase a specific security.
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through the following segments: Human Pharmaceutical Products and Animal Health Products. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health Products segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.